Drug Profile


Alternative Names: Citoplurikin; IRX-2

Latest Information Update: 16 Mar 2017

Price : $50

At a glance

  • Originator IRX Therapeutics
  • Developer IRX Therapeutics; Providence Health & Services
  • Class Antineoplastics; Cytokines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I Breast cancer
  • Preclinical Cancer

Most Recent Events

  • 09 Feb 2017 Phase-I clinical trials in Breast cancer (Early-stage disease, Neoadjuvant therapy) in USA (SC) (NCT02950259)
  • 09 Nov 2016 IRX Therapeutics plans a phase Ib trial for Breast cancer in USA (NCT02950259)
  • 01 Dec 2015 Phase-II clinical trials in Head and neck cancer (Adjuvant therapy, Combination therapy, Late-stage disease, Neoadjuvant therapy, Newly diagnosed) in USA (SC) (NCT02609386)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top